




C14:1/C18:1




C14:1/C18




C14:1/C16




C14:1/C16-OH




C14:1/C14




C14:1/C12




C14:1/C10




C14:1/C8




C14:1/C6




C14:1/C4



C14:1/C3



C14:1/C2 *



C14:1/C0




Figure S2. Ratios of C14:1 to various acylcarnitines and free carnitine in dried blood specimens of newborns. Infants with biallelic *ACADVL* variants and a VLCAD activity of <20% (A-1), 20%–40% (A-2), and >40% (A-3); infants heterozygous for *ACADVL* variants with a VLCAD activity of 20%–40% (B-1) and >40% (B-2); infants with a VLCAD activity of >70% without confirmation by *ACADVL* sequencing (C)

C0, free carnitine

* The graph of the C14:1/C2 ratio is also shown in Figure 1b.